Zenas BioPharma, Inc. (ZBIO)

NASDAQ:
ZBIO
| Latest update: Mar 15, 2026, 7:49 PM

Price Chart

$24.04

1.88%
(1 month)

Top Shareholders

FMR LLC
14.35%
SR One Capital Management LP
9.39%
Enavate Sciences GP LLC
7.30%
NEA Management Co. LLC
6.56%
Federated Hermes, Inc.
5.06%
Fairmount Funds Management LLC
4.12%
Flynn Management LLC
3.74%
Norwest Venture Partners
3.42%

Sentiment for ZBIO

News
Social

Buzz Talk for ZBIO

Today

Social Media

General

Stock events for Zenas BioPharma, Inc. (ZBIO)

ZBIO reached its 52-week high on December 24, 2025. Positive results from the Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease were announced on January 5, 2026. The company announced a late-breaking platform presentation of results from the Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at the ACTRIMS Forum 2026 on February 9, 2026. In early March 2026, the stock price experienced fluctuations around its 50-day and 15-day moving averages. As of March 7, 2026, ZBIO had an AI Score of 6/10 (Hold) from Danelfin. Shareholder investigations by Purcell & Lefkowitz LLP were announced on February 17, 2026, and January 5, 2026.

Demand Seasonality affecting Zenas BioPharma, Inc.’s stock price

Information regarding demand seasonality for Zenas BioPharma, Inc.'s products and services was not available in the provided search results. Demand for its pipeline products, once approved, would likely be driven by disease prevalence and treatment efficacy rather than typical seasonal patterns.

Overview of Zenas BioPharma, Inc.’s business

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company focused on developing and commercializing therapies for autoimmune and rare diseases. The company's lead product candidate is obexelimab, a bifunctional monoclonal antibody being developed for indications such as immunoglobulin G4-related disease, relapsing multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Other programs in the company's pipeline include Orelabrutinib, ZB002, ZB004, ZB001, ZB005, a preclinical oral IL-17AA/AF inhibitor, and a preclinical oral, brain-penetrant, TYK2 inhibitor.

ZBIO’s Geographic footprint

Zenas BioPharma, Inc. serves a global patient population and collaborates with healthcare professionals worldwide. The company is headquartered in Waltham, Massachusetts, United States.

ZBIO Corporate Image Assessment

Specific events directly impacting Zenas BioPharma, Inc.'s brand reputation in the past year were not extensively detailed in the provided search results. Positive clinical trial results for obexelimab are generally positive, while shareholder investigations could potentially have a negative impact.

Ownership

Information regarding major institutional and individual owners of Zenas BioPharma, Inc. was not explicitly detailed in the provided search results. GuruFocus identified "Fairmount Healthcare Fund Ii L.p." in connection with Zenas BioPharma Inc Executives. Simply Wall St provides a "View Ownership" section for Zenas BioPharma, Inc.

FAQ

What is the current stock price of Zenas BioPharma, Inc.?

As of the latest update, Zenas BioPharma, Inc.'s stock is trading at $24.04 per share.

What’s happening with Zenas BioPharma, Inc. stock today?

Today, Zenas BioPharma, Inc. stock is down by -1.88%, possibly due to news.

What is the market sentiment around Zenas BioPharma, Inc. stock?

Current sentiment around Zenas BioPharma, Inc. stock is positive, based on recent news, trading volume, and analyst opinions.

Is Zenas BioPharma, Inc.'s stock price growing?

Over the past month, Zenas BioPharma, Inc.'s stock price has decreased by -1.88%.

How can I buy Zenas BioPharma, Inc. stock?

You can buy Zenas BioPharma, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol ZBIO

Who are the major shareholders of Zenas BioPharma, Inc. stock?

Major shareholders of Zenas BioPharma, Inc. include institutions such as FMR LLC (14.35%), SR One Capital Management LP (9.39%), Enavate Sciences GP LLC (7.30%) ... , according to the latest filings.